The men had either been tested for germline (166), somatic (280), or both types (four) of genetic variants of BRCA1, BRCA2, ATM, CDK12, and PALB2 genes, with a view to starting them on PARP ...

A London-based team led by Alan Ashworth, currently head of the University of California, San Francisco’s cancer center, was working with cells harboring BRCA mutations—genetic perturbations that ...

Many PARP inhibitors have been approved to treat BRCA-mutated cancer types, including some breast and pancreatic cancers. However, BRCA mutations occur in only a small portion of cancer patients. My ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

"Research shows there is a role for PARP inhibitors in cancers associated with DNA repair deficits, such as those with BRCA mutations. In these clinical trials, we wanted to explore whether a PARP ...

We applied the principle of synthetic lethality to discover a novel strategy for cancer treatment for patients with BRCA1 or BRCA2 gene mutations. We demonstrated that drugs called PARP inhibitors ...

also form the basis of a new marketing application for the PARP inhibitor in mCRPC patients, to try to extend its uses. However, the benefit in TRITON3 was almost exclusively in the BRCA-positive ...

5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46] Time of first relapse (years): BRCA ...

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies targeting ALT-positive ...

Best NAD Supplements for Longevity, According to Experts: Wonderfeel Content verified by BrandingEx solutions ...